Product Description
GC203 is a novel non-viral vector gene-modified TIL therapy developed leveraging Juncell Therapeutics' proprietary DeepTIL® cell expansion platform and NovaGMP® gene modification platform. DeepTIL® enables TILs to be potent enough that no IL-2 combination will be required after infusion, and the intensity of pretreatment could be lower. NovaGMP® modifies T cells with a high efficiency comparable with the Lentiviral vector in an economic way. GC203 is engineered with self-associating membrane-bound interleukin-7, which can maintain the stemness of memory T cells, activate internal immune cells and avoid systemic toxicities. (Sourced from: https://www.prnewswire.com/news-releases/juncell-therapeutics-announces-clinical-data-of-gc203-til-therapy-in-ovarian-cancer-at-asco-2024-302155132.html)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Juncell Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Breast Cancer|Gastrointestinal Cancer|Lung Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TIL-JC-DG-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-06-30 |
|
| KUNLUN-001 | P1 |
Recruiting |
Breast Cancer|Gastrointestinal Cancer|Lung Cancer |
2025-11-01 |